3,882.60
+2.54%
Close of 9 Nov 2026, in INR
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Acutaas Chemicals
Its shares trade on NSE under the ticker ACUTAAS.NS. It has been listed since 14 September 2021. In the fiscal year to 31 March 2026, it reported revenue of ₹13.39bn and net income of ₹3.56bn. At that date it held total assets of ₹19.84bn and shareholders' equity of ₹16.54bn.
Acutaas Chemicals Ltd. engages in the development and commercialization of pharmaceutical intermediate products and specialty chemicals. The company is headquartered in Surat, Gujarat. The company went IPO on 2021-09-14. The company is focused on the development and manufacturing of advanced pharmaceutical intermediates (Pharma Intermediates), New Chemical Entities (NCE) and other specialty chemicals for pharmaceuticals, agrochemicals, dyes, polymers, personal care, animal food, and other industries. The company manufactures pharma intermediates for certain active pharmaceutical ingredients (APIs), including dolutegravir, trazodone, entacapone, nintedanib, and rivaroxaban. The pharma intermediates cater to several therapeutic areas, including anti-retroviral, anti-inflammatory, anti-psychotic, anti-cancer, anti-Parkinson, anti-depressant, and anti-coagulant. The company has developed and commercialized over 520 plus products, including specialty chemicals, Pharma Intermediates for APIs across 23 key therapeutic areas since inception and NCE across select high-growth high margin chronic therapeutic areas.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 14 Sept 2021
- Employees
- 676
- Website
- acutaas.com/index.php ↗
Leadership
Pay as last reported
- Mr. Nareshkumar PatelExecutive Chairman of the Board and Managing Director, since 2022₹49.2m
- Mr. Bhavin ShahChief Financial Officer
- Mr. Chetansinh ParmarChief Information Security Officer
- Mrs. Ekta SrivastavaCompany Secretary and Compliance Officer
- Mr. Ram LokhandeWhole Time Director, since 2022₹15.6m
- Mr. Virendra MishraWhole Time Director, since 2021₹13.4m
- Mr. Chetankumar VaghasiaWhole Time Director, since 2007₹48.5m
- Dr. Anita BandyopadhyayNon-Executive Independent Director₹1.0m
- Mr. Hetal GandhiNon-Executive Independent Director₹2.0m
- Mrs. Richa GoyalNon-Executive Independent Director₹1.0m
- Mr. Girikrishna ManiarNon-Executive Independent Director₹2.0m
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 80
- Environment
- 68
- Social
- 99
- Governance
- 72
- Direct emissions (scope 1)
- 37,054 t
- Energy emissions (scope 2)
- 12,753 t
- Value chain emissions (scope 3)
- 14,498 t
- Women in the workforce
- 6.5%
- Carbon reduction policy
- No
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Acutaas Chemicals Ltd develops 520+ specialty chemicals and Pharma Intermediates for 23 therapeutic areas.
- The company manufactures intermediates for APIs like dolutegravir and rivaroxaban used in anti-retroviral and anti-coagulant treatments.
- Acutaas focuses on high-margin chronic therapeutic areas with New Chemical Entities (NCE) for growth.
Weaknesses
- The company has 676 employees which is relatively small for a pharmaceutical manufacturer.
- Acutaas Chemicals Ltd is headquartered in Surat, Gujarat, a location with limited global pharmaceutical infrastructure.
- The company's IPO was on 14 September 2021, indicating recent market entry.
Opportunities
- Acutaas can expand its NCE portfolio in high-growth chronic therapeutic areas like anti-cancer and anti-depressant markets.
- The company's 520+ products can be leveraged to enter new markets in agrochemicals and personal care industries.
- Acutaas Chemicals Ltd can grow by targeting the increasing demand for anti-retroviral treatments globally.
Threats
- Acutaas faces competition from larger pharmaceutical manufacturers in the global market.
- The company's reliance on specific APIs like dolutegravir may expose it to supply chain disruptions.
- Acutaas Chemicals Ltd operates in a highly regulated industry with potential compliance risks.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.